β2-AR

Monocyte/macrophage β2-AR as a target of antisympathetic excitation-induced atherosclerotic progression

Y. L. Guo, Zhou, J. Q., Xiang, C. Q., Yang, W. H., Zhang, B., Dai, W. J., Liu, J. H., and Zheng, S. J., Monocyte/macrophage β2-AR as a target of antisympathetic excitation-induced atherosclerotic progression, vol. 13, pp. 8080-8088, 2014.

The aim of this study was to determine whether monocyte/macrophage β2-AR could act as the therapeutic target of antisympathetic excitation-induced atherosclerotic progression. Cultivated human THP-1 cells were divided into different groups and incubated with isoprenaline, metoprolol, propranolol or β2-AR blocker for 24 h, together with oxidized low-density lipoprotein (ox-LDL). Afterwards, each group was analyzed for C-C chemokine receptor type 2 (CCR2) expression, monocyte chemotactic protein 1 (MCP-1) release into medium and cell migration ability.

Subscribe to β2-AR